Development of a novel lead that targets M. tuberculosis polyketide synthase 13

Published Date:

11/30/2018

Source:

Cell

Authors:

Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha, R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snavely T, Robertson GT, Rubin EJ, Ioerger TR, Sirgel EA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts A.J, Sacchettini JC

External link

Original Article

Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacological and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection.

Events

«

June 2019

»
S
M
T
W
T
F
S
·
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·
·
·
·
·

Projects

Modeling to improve TB decision-making in the...

We are part of a large consortium that is constructing epidemic and economic models of TB and HIV in collaboration with the U.S....

Read More

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More

Enhancing models of HIV,viral hepatitis,...

The goal of this five-year project is to assist the United States Centers for Disease Control and Prevention in their approach...

Read More

A novel “shock and kill” strategy...

The objective of this study is to determine if pharmacological inhibition of the Mtb stringent response leads to accelerated...

Read More

Quantiferon gold test for detecting TB...

This is a cluster randomized trial comparing the time to known latent TB status among HIV infected patients receiving QGIT...

Read More